Alaunos Therapeutics (TCRT) FCF Margin (2016 - 2025)
Alaunos Therapeutics (TCRT) has disclosed FCF Margin for 13 consecutive years, with 38600.0% as the latest value for Q1 2025.
- For the quarter ending Q1 2025, FCF Margin rose 15310000.0% year-over-year to 38600.0%, compared with a TTM value of 48483.33% through Sep 2025, up 14758333.0%, and an annual FY2024 reading of 49710.0%, up 55707000.0% over the prior year.
- FCF Margin was 38600.0% for Q1 2025 at Alaunos Therapeutics, down from 14800.0% in the prior quarter.
- Across five years, FCF Margin topped out at 65872.73% in Q4 2022 and bottomed at 774250.0% in Q4 2021.
- Average FCF Margin over 5 years is 191472.74%, with a median of 40312.5% recorded in 2024.
- The sharpest move saw FCF Margin skyrocketed 84012273bps in 2022, then tumbled -80437273bps in 2023.
- Year by year, FCF Margin stood at 774250.0% in 2021, then skyrocketed by 109bps to 65872.73% in 2022, then crashed by -1221bps to 738500.0% in 2023, then skyrocketed by 98bps to 14800.0% in 2024, then crashed by -161bps to 38600.0% in 2025.
- Business Quant data shows FCF Margin for TCRT at 38600.0% in Q1 2025, 14800.0% in Q4 2024, and 42025.0% in Q2 2024.